Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

622 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost effectiveness of external hip protectors in the hospital setting: a modeling study.
Stollenwerk B, Waldeyer R, Klein-Meding C, Müller D, Stock S. Stollenwerk B, et al. Among authors: stock s. Nurs Econ. 2014 Mar-Apr;32(2):89-98. Nurs Econ. 2014. PMID: 24834633
Hip fractures not only have devastating consequences on an individual's quality of life but may also affect a hospital's reputation in the community. ...
Hip fractures not only have devastating consequences on an individual's quality of life but may also affect a hospital's reput …
Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
Stollenwerk B, Bartmus T, Klug F, Stock S, Müller D. Stollenwerk B, et al. Among authors: stock s. Osteoporos Int. 2015 Apr;26(4):1367-79. doi: 10.1007/s00198-014-3008-7. Epub 2015 Jan 9. Osteoporos Int. 2015. PMID: 25572047
Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes.
Müller D, Borsi L, Stracke C, Stock S, Stollenwerk B. Müller D, et al. Among authors: stock s. Eur J Health Econ. 2015 Jun;16(5):517-27. doi: 10.1007/s10198-014-0605-5. Epub 2014 May 13. Eur J Health Econ. 2015. PMID: 24818587
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Zindel S, Stock S, Müller D, Stollenwerk B. Zindel S, et al. Among authors: stock s. BMC Health Serv Res. 2012 Jul 9;12:192. doi: 10.1186/1472-6963-12-192. BMC Health Serv Res. 2012. PMID: 22776616 Free PMC article.
[Postoperative multimodal pain management : Cost-minimisation analysis from a hospital's point of view].
Bernschein A, Redaèlli M, Stock S. Bernschein A, et al. Among authors: stock s. Schmerz. 2010 Aug;24(4):373-9. doi: 10.1007/s00482-010-0930-2. Schmerz. 2010. PMID: 20490570 German.
Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective.
Drabik A, Büscher G, Sawicki PT, Thomas K, Graf C, Müller D, Stock S. Drabik A, et al. Among authors: stock s. Diabetes Res Clin Pract. 2012 Feb;95(2):194-200. doi: 10.1016/j.diabres.2011.09.015. Epub 2011 Oct 17. Diabetes Res Clin Pract. 2012. PMID: 22004943
Asthma: prevalence and cost of illness.
Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Stock S, et al. Eur Respir J. 2005 Jan;25(1):47-53. doi: 10.1183/09031936.04.00116203. Eur Respir J. 2005. PMID: 15640322
[Checklist for the Development and Assessment of Cost-of-Illness Studies].
Müller D, Stock S, Dintsios CM, Chernyak N, Gerber-Grote A, Gloede TD, Hermann B, Huppertz E, Jülich F, Mostardt S, Köberlein-Neu J, Prenzler A, Salize HJ, Santos S, Scheckel B, Seidl A, Wahlers K, Icks A. Müller D, et al. Among authors: stock s. Gesundheitswesen. 2018 Aug;80(8-09):744-753. doi: 10.1055/s-0042-124664. Epub 2017 May 18. Gesundheitswesen. 2018. PMID: 28521377 German.
Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework.
Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PW, Frey S, Adarkwah CC, de Kinderen R, Hellmich M. Müller D, et al. Among authors: stock s. Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):619-627. doi: 10.1586/14737167.2016.1115721. Epub 2015 Dec 17. Expert Rev Pharmacoecon Outcomes Res. 2016. PMID: 26548753
Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.
Auweiler PW, Müller D, Stock S, Gerber A. Auweiler PW, et al. Among authors: stock s. Pharmacoeconomics. 2012 Jul 1;30(7):537-49. doi: 10.2165/11591160-000000000-00000. Pharmacoeconomics. 2012. PMID: 22612993 Review.
BACKGROUND: The monoclonal antibody rituximab has shown clinical effectiveness in combination with chemotherapy for the treatment of non-Hodgkin's lymphoma (NHL) in several randomized controlled studies. ...
BACKGROUND: The monoclonal antibody rituximab has shown clinical effectiveness in combination with chemotherapy for the treatment of non-Hod …
622 results
Jump to page
Feedback